

Piazza Fabrizio

Pharmaceutical Biotechnologist, Ph.D.

Date and place of birth: 17/01/1979, Lecco - Italy

Address for correspondence: Via Cadore, 48.

20900. Monza –MB

e-mail: fabrizio.piazza@unimib.it



Google Scholar: **H Index (i10-Hindex): 16 (19)**

Citations: 595

Scopus: **H index: 13 (last 10 years)**

Citations: 419

Abilitazione Scientifica Nazionale (ASN 2017):

**06/N1 - SCIENZE DELLE PROFESSIONI SANITARIE E DELLE TECNOLOGIE
MEDICHE APPLICATE (from 31/03/2017 to 31/03/2023)**

Researcher identifier: Google Scholar: <http://scholar.google.it/citations?user=Kzv0tukAAAAJ>

Web Site URL: <https://sites.google.com/site/icabinternationalnetwork>

CURRENT POSITIONS

- 2009 – *to date* Senior Postdoc Associate (Assegnista di Ricerca A2 Senior), UNIMIB, (Phone 02.64488128)
- 2017 – *to date* Research Associate, Istituto di Tecnologie Biomediche (ITB), Consiglio Nazionale delle Ricerche (CNR), Segrate, Italy
- 2016 – *to date* Principal Investigator (Team Leader of the CAA and AD Translational Research and Biomarkers) (Phone 02.64488128)
- 2011 – *to date* Founding Member and Coordinator of the inflammatory Cerebral Amyloid Angiopathy and Alzheimer's disease β biomarkers (*iCA β*) International Network, School of Medicine and Surgery, Milan Center for Neuroscience (NeuroMI), University of Milano-Bicocca (UNIMIB), Monza, Italy (Phone 02.64488128)

EDUCATION

- Sept. 2005 Doctor in Pharmaceutical Biotechnology (Advisor Prof. M. DiLUCA). University of Milano, Italy
- Nov. 2008 International Ph.D. in Translational and Molecular Medicine (Advisor Prof A. BIONDI). UNIMIB, Monza, Italy

POST-Ph.D. MASTERS, INTERNATIONAL SCHOOL

- 2006 Stem Cell Research, Innovation and Perspectives, Università di Milano, Milano
- 2007 Statistical Analysis of Biological data, Molecular Biotech Centre, Torino
- 2007 European Neuroscience School, Novel Molecular Strategies to Treat Neurodegenerative Diseases, University of Coimbra, Portugal
- 2009 European Neuroscience School, Metabolic Aspects of Chronic Brain Disease, Ulm University, DE
- 2011 ESNI School of Neuro-Immunology, Glasgow University, UK

2012 ISNI School of Neuro-Immunology, Harvard University, Boston, MA, USA

PREVIOUS POSITIONS

- 2005-09 MIUR Scholarship (1st classified) (Head Prof. C. Ferrarese). *Lab Neurobiology. UNIMIB, IT*
- 2008 Visiting Researcher. (Head Alberico Catapano). *Lab Molecular Genetics and Cardio. Genomics, IT*
- 2009-2010 Postdoc Associate. (Head Prof. G. Tesco). *Lab. of Alzheimer's disease. Tufts University and Harvard Medical School, Boston, MA, USA*
- 2012-13 Visiting Researcher (Head Fabrizio Tagliavini). *Dept. of Neuropathology-Neurology. IRCCS Besta, IT*

FELLOWSHIPS, AWARDS AND HONORS

- 2007 **European Stroke Conference Distinction**
- 2007 **“Ingenio” Award**, Regione Lombardia-European Social Fund
- 2008 **Fellowship** Molecular Mechanisms in Neuroscience
- 2009 **Novartis European Biotechnology Leadership Camp**, top 40 researchers selection, Basel
- 2009 **Fellowship**, Progetto Professionalità Ivano Becchi
- 2012 **Fellowship**, International Society of NeuroImmunology (ISNI)
- 2013 **Fellowship**, Italian Society of Neuroscience (SINS)
- 2013 **AD/PD International Conference Faculty Award**
- 2013 **Perusini Award** for best 2013 Research on Alzheimer, Italian Neurology Society (SINdem)
- 2014 **AAIC Fellowship**, Alzheimer's Association International Congress
- 2017 **Rita Levi Montalcini Young Italian Investigator Award**. AAT-AD/PD 2018.

EDITORIAL BOARD MEMBER

- 2014 Journal Neuroimmunology and Neuroinflammation
- 2015 Journal of Alzheimer's Disease
- 2015 Journal of Clinical Trials & Patenting
- 2017 Current Advances in Neurology and Neurological Disorders
- 2017 Frontiers in Molecular Neuroscience
- 2017 Brain & Neuroscience Research

INTERNATIONAL MEETINGS BOARD MEMBER (Role)

- 2007 PENS (Chairman), Coimbra, Portugal
- 2016 SINdem (Symposium Organizer, Chairman), Florence, Italy
- 2016 to date Alzheimer's Association International Conference (Scientific Abstract Board), Toronto, Canada, and London UK
- 2016 2nd International NeuroMI Meeting (Faculty Board), Milan, Italy

REVIEW BOARD MEMBER: Journal of Alzheimer's Disease. British Medical Journal. Journal of Neurology. Neurobiology of Aging. BioMetals. Neurol Sci, PlosOne, Alzh. Disease and Ass. Dementia, Frontiers in Neurology, Frontiers in Molecular Neuroscience, Alzheimer's and Dementia: Translational Research and Clinical Interventions

GRANT EVALUATOR:

- 2013 Agence Nationale de la Recherche, French Call for Translational Research
- 2016 Expert Reviewer for the three European funding organizations on Alzheimer's disease:
- LECMA (LIGUE EUROPÉENNE CONTRE LA MALADIE D'ALZHEIMER, France)
 - AFI (ALZHEIMER FORSCHUNG INITIATIVE e. V. Germany)

- ISAO (INTERNATIONALE STICHTING ALZHEIMER ONDERZOEK, The Netherlands) 2017. The Netherlands Organisation for Health Research and Development (ZonMw), Memorabel Research and Innovation Program for Dementia.
- 2017. Weston Brain Institute. Toronto. Canada.

MEMBERSHIPS OF INTERNATIONAL SCIENTIFIC SOCIETIES

AAIC, ISTAART, FENS, IBRO, SINS, SIndem, AINI, ISNI, International CAA Association, EADC, Clinical Trials Advancement and Methods PIA member, AAAS (American Association for the Advancement of Science)

INSTITUTIONAL RESPONSIBILITIES

2014-2018 Coordinator of the iCA β -ITALY Study Group of the Italian Society of Neurology-dementia. A Study Group for the establishment of clinical and diagnostic recommendation in CAARI clinical practice.

2015-to date European Alzheimer's Disease (EADC) Centers of Excellence, Stable Board Member Representative for UNIMIB

2014-to date. Technology Transfer Office (TTO) Responsible for the School of Medicine.

SUPERVISION OF GRADUATE STUDENTS AND POSTDOCTORAL FELLOWS

2009-to date Advisor for more than 15 Students in Medical Biotechnology, Medicine and Specialty in Neurology.

2009-to date External Reviewer for 4 Students in Medical Biotechnology

2008-2009 Tutor for 3 PIs (funded grants) at the Sovvenzione Globale Ingenio- Regione Lombardia- European Social Found 2008

TEACHING ACTIVITIES

2005- to date. Contract Professor at the School of Medical Biotechnology, UNIMIB

2006. Second Level Master Degree in Cerebrovascular diseases, UNIMIB and S. Gerardo Hospital

2014. Contract Professorship, Apporto diagnostico del Lab. di neurobiologia nelle patologie neurologiche. Vicenza Hospital

2016. Contract Professorship at the Italian Society of Neurology-Dementia (SINDEM)

2016. Contract Professorship at the Milan Center for Neuroscience (NeuroMi) Prediction and prevention of dementia: new hope.

MAJOR COLLABORATIONS IN INTERNATIONAL NETWORKS

2015-to date European Network of Alzheimer's Disease Centers of Excellence (EADC)

2012-to date **Coordinator** of the iCA β International Network, involving 33 Centres from 12 Countries World-Wide

2012-to date BIOMARKAPD. Joint Programming Neurodegenerative disease (JPND), Coordinator: B. Winblad

2014-to date IVASCOMAR Network, Coordinator: Giancarlo Comi

2007- 2013 FP7-Nanoparticles for Alzheimer's Disease (NAD), Coordinator: M. Masserini

PATENTS (granted)

Ultra sensible technique and related KIT for Abeta antibodies and TFPI dosage in CSF

- 1) **International Patent # PCT/IB2013/052206- WO 2013/140349 – PCT Released (2017)**
- 2) **Italian Patent # RM20120383 – GRANTED (2015)**

PEER-REVIEWED PUBLICATIONS (21/40 publications as FIRST-LAST Author)

Stabile A, Di Lazzaro V, Colosimo C, **Piazza F**, Ferrarese C, DiFrancesco JC.
Idiopathic infratentorial superficial siderosis of the central nervous system: case report and review of literature.

Neurol Neurochir Pol. 2017 Oct 27

IF: 0.9

Piazza F.

IV immunoglobulin for the treatment of Alzheimer's disease: no ARIA, no Win?

Neurology. Jan. 2018.

IF: 8.3

DiFrancesco Jacopo C, Longoni Martina, Pascarella Rosario, Marconi Roberto, Perini Francesco, Villarejo-Galende Alberto, Cirillo Mario, Zedde Marialuisa, **Piazza Fabrizio.**

Pharmacological Treatment of Cerebral Amyloid Angiopathy-related inflammation.

Nature npg Scientific Reports. 2017. *Under Review.*

IF: 5.2

Colombo I; Calabrese G; Bordo B; Chiapparini I; Auricchio S; **Piazza F**; Longoni M; Santilli I.

Abrupt withdrawal of immunosuppressive drugs: a potential trigger for CAA-ri.

Neurological Sciences. 37.S52. October2016

IF: 1.8

Piazza F and Winblad B.

Amyloid-Related Imaging Abnormalities (ARIA) in immunotherapy trials for Alzheimer's disease: need for prognostic biomarkers?

Journal of Alzheimer's Disease. 2016 Mar 29

IF: 4.2

Eitan A; Charidimou A; Edip GM; Jun N; Van Etten ES,; Martinez-Ramirez S; **Piazza F**; DiFrancesco JC; Frosch M; Pontes-Neto O; Shoamanesh A; Reijmer Y; Vashkevich A; Ayres A; Schwab KM; Viswanathan A; Greenberg S.

Validation of clinical-radiological criteria for the diagnosis of cerebral amyloid angiopathy-related inflammation.

JAMA Neurol. 2016 Feb 1;73(2):197-202

IF: 8.3

Iragui MC, Arcos AF, Alcolea D, **Piazza F**, Morenas E, Aguirre SA, Sala I, Clarimon J, Icardo OD, Camacho V, Sampedro F, Munuera J, Marin FN, Lleó A, Fortea J, Ansón BG and Blesa R. Cerebrospinal fluid anti-A β autoantibodies and Amyloid PET in Cerebral Amyloid Angiopathy-related Inflammation.

Journal of Alzheimer's Disease. 2015 Nov 27;50(1):1-7.

IF: 4.2

DiFrancesco JC, Longoni M, **Piazza F.**

Anti-A β autoantibodies and Amyloid Related Imaging Abnormalities: biomarkers for disease modifying clinical trials in Alzheimer's disease and Cerebral Amyloid Angiopathy. Research Topic Review in: Biomarkers of Alzheimer's disease: the present and the future.

Frontiers in Neurology 2015. 6:207. doi: 10.3389/fneur.2015.00207.

IF: 3.6

F. Piazza, S.M. Greenberg, B. Winblad, N. Fox, et al.
CSF biomarkers for amyloid related imaging abnormalities (ARIA) in immunotherapy trials of Alzheimer's disease and Cerebral Amyloid Angiopathy: report from the iCA β international network.
The Journal of Prevention of Alzheimer's Disease – OC 23, Volume 2, Number 4, 2015.

Anti-amyloid beta autoantibodies: treatment implications in cerebral amyloid angiopathy-related Inflammation.

Martina Longoni & **Fabrizio Piazza**

J Neuroimmune Pharmacol. 2015. DOI 10.1007/s11481-015-9649-2

IF: 4.1

Crosta F, Orlandi B, De Santis F, Passalacqua G, DiFrancesco JC, **Piazza F**, Catalucci A, Desideri G and Marini C.

Cerebral Amyloid Angiopathy-Related Inflammation: Report of a Case with Very Difficult Therapeutic Management.

Case Reports in Neurological Medicine. 2015;2015:483020.

DiFrancesco JC, Touat M, Caulo M, Gallucci M, Garcin B, Levy R, Uncini A and **Piazza F**.
Recurrence of Cerebral Amyloid Angiopathy-related inflammation: a report of two cases from the iCA β International Network.

Journal of Alzheimer's Disease 2015. vol. 46, no. 4, pp. 1071-1077

IF: 4.2

Piazza F*, Boncoraglio GB*, Savoiaro M, Farina L, DiFrancesco JC, Prioni S, Tagliavini F, Parati EA, Giaccone G. (* Co-First name-equal contribution)

Prodromal AD presenting with spontaneous ARIA and high cerebrospinal fluid anti-A β autoantibodies.

Journal of Alzheimer's Disease. 2015 Jan 1;45(2):363-7

IF: 4.2

Piazza F*, Musumeci R *, Cocuzza C, Oggioni D, Androni S, Giardinetti M, Fusco L, Frigo M, Banfi P, Rottoli MR, Gonfalonieri P, Rezzonico M, Ferro MT, Cavaletti G.

Quantitative Detection of Epstein-Barr Virus DNA in Cerebrospinal Fluid and Blood Samples of Patients with Relapsing-Remitting Multiple Sclerosis: Overcoming controversies due to technical issues.

PLOS ONE 2014 Apr10;9(4):e94497 (* Co-First name-equal contribution)

IF: 4.1

E Auriel, ME Gurol, J Ni, E Van Etten, S Martinez-Remirez, **F Piazza**. et al.

Validation of Clinical-Radiological Criteria for the Diagnosis of Cerebral Amyloid Angiopathy-related Inflammation.

Stroke 2014. 45 (Suppl 1), AWMP89-AWMP89

IF: 5.72

M Carmona-Iragui, A Fernández-Arcos, D Alcolea, **F Piazza** et al.

Biomarkers In Cerebral Amyloid Angiopathy-Related Inflammation

Alzheimer's and Dementia 07/2014; 10(4):P519

IF: 17.47

Anti-A beta autoantibody in CAA-ri and AD: different singers for the same ARIA? Report from the iCAB International Network.

F Piazza, SM Greenberg, AL Bisa, R Nitrini, H Sakaguchi, Y Hagiwara, et al.

Journal of Alzheimer's disease 2014.41, S38-S39

IF: 4.2

F Piazza, SM Greenberg, et al.

Anti-A β autoantibodies in CAA and AD: different singers for the same ARIA?

Alzheimer's and Dementia 07/2014; 10(4):P221

IF: 17.47

Melcangi RC, Caruso D, Abbiati F, Giatti S, Calabrese D, **Piazza F**, Cavaletti G.

Neuroactive Steroid Levels are Modified in Cerebrospinal Fluid and Plasma of Post-Finasteride Patients Showing Persistent Sexual Side Effects and Anxious/Depressive Symptomatology.

J Sex Med. 2013 Oct;10(10):2598-603

IF: 3.5

Piazza F, Greenberg SM, Savoiardo M, Gardinetti M, Chiapparini L, Raicher I, Nitrini R, Sakaguchi H, Brioschi M, Billo G, Colombo A, Lanzani F, Piscosquito G, Carriero MR, Giaccone G, Tagliavini F, Ferrarese C, DiFrancesco JC.

Anti-A β autoantibodies in Cerebral Amyloid Angiopathy-related inflammation: implications for amyloid-modifying therapies.

Annals of Neurology, 2013, Feb 11

IF: 11.1

Piazza F, Galimberti G, E Conti, V Isella, MV Perlangeli, T Speranza, B Borroni, EM Pogliani, A Padovani, and C Ferrarese.

Increased Tissue Factor Pathway Inhibitor and Homocysteine in Alzheimer's disease.

Neurobiol Aging. 2012 vol. 33, p. 226-233

IF: 6.6

Piazza F, SM Greenberg, et al.

Autologous anti-A β antibodies in CAA-ri: New biomarker for detection of amyloid-related imaging abnormalities (ARIA) during Abeta-disease modifying therapies for AD.

Neurol Sci 2013. 333, e329-e329

IF: 2.4

Ferrarese C and **Piazza F**. Vascular damage and neurodegeneration.

Journal of Alzheimer's Disease 2012, 29 (S1), Pages 23-242.

IF: 4.2

Kang EL, Biscaro B, **Piazza F**, Tesco G.

BACE1 Protein Endocytosis and Trafficking Are Differentially Regulated by Ubiquitination at Lysine 501 and the Di-leucine Motif in the Carboxyl Terminus.

The Journal of Biological Chemistry 2012. Vol 287, 51, 14. 42867-42880

IF: 4.8

Cavaletti G, Fusco ML, Giardinetti M, Cogo M, Androni S, **Piazza F**. Pathogenetic similarities shared by Alzheimer's disease and multiple sclerosis.

Journal of Alzheimer's Disease 2012, 29 (S1), Pages 23-242.

IF: 4.2

K.A. Kittelberger, **F Piazza**, G Tesco, LG. Reijmers.
Natural Amyloid-beta oligomers acutely impair the formation of a contextual fear memory in mice.
PLoS One. 2012;7(1):e29940.

IF: 4.1

A Bulbarelli, E Lonati, A, Brambilla; A Orlando; E Cazzaniga, **F Piazza**, C Ferrarese, M Masserini, G Sancini.

A β 42 production in brain capillary endothelial cells after oxygen and glucose deprivation.
Molecular and Cellular Neuroscience 2012 vol. 49;4, 415-22.

IF: 3.7

Piazza F*, DiFrancesco JC*, E Conti, L Tremolizzo, M Savoiaro, C Ferrarese.

Anti-Abeta autoantibodies in cerebral amyloid angiopathy related inflammation: a role for pathogenesis?

Journal of Neurology, Neurosurgery & Psychiatry, 24 June 2011.

IF: 4.8

Beretta S, Pastori C, Sala G, **Piazza F**, Ferrarese C, Cattalini A, de Curtis M, Librizzi L.

Acute lipophilicitydependent effect of intravascular Simvastatin in the early phase of focal cerebral ischemia.

Neuropharmacology. 2011 Jan 12.

IF: 4.9

Piazza F and Ferrarese C.

Interplay between immunity, neurodegeneration and endothelial perturbation in Alzheimer's disease patients.

Journal of Alzheimer's Disease 2011

IF: 4.2

Conti E, Galimberti G, Tremolizzo L, Masetto A, Cereda D, Zanchi C, **Piazza F**, Casati M, Isella V, Appollonio I, Ferrarese C.

Cholinesterase inhibitor use is associated with increased plasma levels of anti-Abeta 1-42 Antibodies in Alzheimer's disease patients.

Neurosci Lett. 2010 Dec 17;486(3):193-6.

IF: 2.1

Prigione A, **Piazza F**, Brighina L, Begni B, Galbussera A, DiFrancesco JC, Andreoni S, Piolti R, Ferrarese C.

Alpha-synuclein nitration and autophagy response are induced in peripheral blood cells from patients with Parkinson disease.

Neurosci Lett. 2010 Jun 14;477(1):6-10

IF: 2.1

Piazza F, DiFrancesco JC, Fusco ML, Corti D, Pirovano L, Frigeni B, Mattavelli L, Andreoni S, Frigo M, Ferrarese C, Tredici G, Cavaletti G.

Cerebrospinal fluid levels of BAFF and APRIL in untreated multiple sclerosis.

J Neuroimmunol. 2010 Mar 30;220(1-2):104-7

IF: 3.1

Kang EL, Cameron AN, **Piazza F**, Walker KR, Tesco G.

Ubiquitin regulates GGA3-mediated degradation of BACE1.

J Biol Chem. 2010 Jul 30;285(31):24108-19.

IF: 5.3

Tibolla G, Norata GD, Meda C, Uboldi P, **Piazza F**, Ferrarese C, Maggi A, Vegeto E, Catapano AL. Increased atherosclerosis and vascular inflammation in a mouse model of Alzheimer's disease. **Atherosclerosis**. 2010 May;210(1):78-87.

IF: 4.5

Conti E, Galimberti G, **Piazza F**, Raggi ME, Ferrarese C. Increased soluble APPalpha, Abeta 1-42, and anti-Abeta 1-42 antibodies in plasma from down syndrome patients.

Alzheimer Dis Assoc Disord. 2010 Jan-Mar;24(1):96-100

IF: 2.6

Tremolizzo L, **Piazza F**, Longoni M, Ferrarese C.

Platelets might mediate the increase of plasma glutamate in acute ischemic stroke: relevance for early neurological deterioration.

Med Hypotheses. 2009 Oct;73(4):553-4

IF: 1.4

Galimberti G, Conti E, Zini M, Piazza F, Fenaroli F, Isella V, Facheris M, Perlangeli V, Antolini L, DeFilippi F, Ferrarese C.

Post-methionine load test: A more sensitive tool to reveal hyperhomocysteinemia in Alzheimer patients?

Clin Biochem. 2008 Jul;41(10-11):914-6

IF: 1.9

Piazza F, M Longoni, I Guerrato, C Ferrarese.

Effect Of Tnf-Alpha On Platelet Glutamate Uptake In Stroke Patients.

Cerebrovascular Diseases 2007, vol. 23 suppl 2, pp. 57-80.

IF: 2.9

C Ferrarese, **F Piazza**, L Tremolizzo, M Longoni.

Markers Periferici Di Danno Neuronale Ischemico

Neurol Sci 2006

IF: 1.4

RESEARCH MONOGRAPHS

Piazza F., G. Galimberti, E. Conti, I. Guerrato, V. Isella, T. Speranza, B. Borroni, E.M. Pogliani, A. Padovani and C. Ferrarese. Endothelial Damage And Platelet Activation In Alzheimer's Disease Patients. Alzheimer's & Parkinson's diseases: advances, concepts & new challenges, March 11-15, 2009. **Medimond**

**LECTURES AND INVITED PRESENTATIONS TO PEER-REVIEWED,
INTERNATIONAL CONFERENCES**

34 invited Speaker Oral Presentations

Pharmacological Treatment of Cerebral Amyloid Angiopathy-related inflammation. Implications for Immunotherapy-induced ARIA.

AAT - AD/PD 2018. March 2018.

Amiloidopatia cerebrale ed infiammazione.

Università di Salerno. Aprile 2017

The ARIA paradox: off-key or keynote in the opera of immunotherapy?

ADPD International Conference, March 2017. Vienna.

Validation of CSF anti-A β autoantibodies and tissue factor pathway inhibitor as diagnostic and prognostic biomarkers of cerebral amyloid angiopathy-related inflammation.

ADPD International Conference, April 2017. Vienna.

The ARIA paradox in AD and CAA: merely an adverse event or an out of tune proof of immunotherapy effectiveness? Symposium Immunotherapy Trials in CAA and AD

5th International CAA Conference, Sept 2016, Broad Institute MIT and Harvard, Boston, MA

Non-vascular leucoencephalic dementia: The case of Cerebral Amyloid Angiopathy related inflammation

XLVII Italian Neurological Society Meeting, 22-25 Oct. 2016, Venezia

Anti Amyloid Antibodies in CSF.

Early diagnosis of dementia: le nuove possibilità cliniche e strumentali, 11 Oct. 2016, Vicenza

Diagnostic Criteria and novel Biomarkers of CAA-related inflammation

Lecture at Dept. Neurology, Università di Genova, 15 luglio 2016, Genova

Anti- β antibodies in CSF: markers for therapies?

2 International Meeting of the Milan Center For Neuroscience (NEUROMI), July 2016, Milan

The Inflammatory Cerebral Amyloid Angiopathy and Alzheimer's Disease β biomarkers—Italy (iCA β -Italy) SINDem Study Group. From clinical practice to new research opportunities in Cerebral Amyloid Angiopathy: presentation of the newborn iCAB-Italy SINDem Study Group.

Italian Society of Neurology for Dementia (SINDem). Firenze, March 2016

TransportDementia

ABC transporter BBB, Oslo, Norway, 9-11 Dec. 2015

Plenary lecture

Annual Meeting of the Spanish Society of Neurology. November 18, 2015, Valencia, Spain

CSF biomarkers for ARIA in immunotherapy trials for AD and CAA: report from the iCA β International Network.

8th Clinical Trials on Alzheimer's Disease (CTAD 2015), Barcelona, November 5-7, 2015

Inflammatory Cerebral Amyloid Angiopathy and new immunological trials in Alzheimer's disease.

Alzheimer: from Amyloid to dementia. Neurocenter from Southern Switzerland, Sept. 2015

Recurrence of Cerebral Amyloid Angiopathy-related inflammation: a report of two cases from the *iCA β* -Italy SINDem Study Group and *iCAB* International Network.

Italian Society of Neurology for Dementia (SINDem). Genova, March 2015

CSF anti-A β autoantibodies as novel biomarker for Cerebral Amyloid Angiopathy-related inflammation: implications for amyloid-related imaging abnormalities (ARIA) during passive immunization in AD.

2nd International Conference on Alzheimer's disease & Dementia, Sept 23-25, 2014, Valencia, Spain

Inflammatory CAA mechanisms and biomarkers—lessons for sporadic CAA diagnosis and treatment.

4th International CAA Conference, London, UK, 18-20 September 2014

Anti-A β autoantibodies in CAA-ri vs AD patients: different singers for the same ARIA?

Alzheimer's Association International Conference 2014 (AAIC), July 2014, Copenhagen, DK

Anti-A β autoantibody in CAA-ri and AD: different singers for the same ARIA? Report from the *iCA β* International Network.

Italian Society of Neurology for Dementia (SINDem), Florence 13-15 March 2014

Anti-A β autoantibodies and endothelial damage during spontaneous amyloid-related imaging abnormalities (ARIA): report from the *iCA β* Network

Congress of the Italian Society of Neurology (SIN), Milan 2013

Pathogenetic role of CSF anti-A β autoantibodies in CAA-related inflammation and Alzheimer's disease: a novel biomarker for the Amyloid Related Imaging Abnormalities for amyloid-modifying therapies

Congress of the Italian Society of Pharmacology (SIF), Milan 2013

Anti-A β autoantibodies and endothelial damage during spontaneous Amyloid-Related Imaging Abnormalities (ARIA): report from the inflammatory cerebral amyloid angiopathy and alzheimer's disease biomarkers collaborative network (*iCAB*)

8th International Congress on Vascular Dementia – ICVD 2013, Athens, Greece, October 17-20, 2013

Autologous anti-A β antibodies in CAA-ri: new biomarker for detection of Amyloid-Related Imaging Abnormalities (ARIA) during A β -disease modifying therapies for AD

XXI World Congress of Neurology, Vienna, Austria, 21-26 Sept, 2013

Anti-A β autoantibodies in Cerebral Amyloid Angiopathy-related inflammation: a human spontaneous model of amyloid-related imaging abnormalities (ARIA) in Alzheimer's disease

Italian Society of Neurology for Dementia (SINDem), Perugia 13-15 March 2013

Pathogenetic Role of Anti- A β Autoantibodies in CAA-related Inflammation: Implications for Amyloid-modifying Therapies in AD

11th International Conference on Alzheimer's & Parkinson's Diseases (ADPD 2013), Florence, Italy. March 6-10, 2013

Immune-mediated mechanisms in the pathogenesis of Cerebral Amyloid Angiopathy-related inflammation and Alzheimer's disease: role of anti-A β auto-antibodies

11th International Society of Neuroimmunology (ISNI), November 04 - 08, 2012, Boston, MA - USA

Auto-antibodies to A β in CSF

MGH and Harvard Medical School Stroke Research Meeting, 2012. Boston, MA, USA

Cerebral Amyloid Angiopathy-related inflammation

Tufts School of Medicine Seminars, November 09th, 2012, Boston, MA – USA

Pathogenetic role of anti-A β autoantibodies in CAA-related inflammation and Alzheimer's disease

XLIII Congress of the Italian Society of Neurology (SIN), Rimini 2012

Endogenous BACE1 is mono- and K63-linked poly-ubiquitinated at Lysine 501.

Society for Neuroscience 2010. San Diego, CA, USA

Vascular damage in Alzheimer's disease patients

Global Novartis Biocamp 2009 Cambridge, MA, USA

GRANT HISTORY

<i>Project Title</i>	<i>Funding source</i>	<i>Period</i>	<i>Role of the PI</i>
Anti-A β autoantibodies and Amyloid Related Imaging Abnormalities (ARIA): biomarkers for Cerebral Amyloid Angiopathy-related inflammation and Alzheimer's disease clinical trials. (BiomarkARIA)	Young Researcher Starting Grant (Caripllo Foundation)	2016-2019	Principal Investigator
Biomarkers of Vascular Function and Integrity in Cerebral Amyloid Angiopathy: A Prospective Longitudinal Cohort Study	Canadian Institutes of Health Research	2015-2020	Principal Investigator (Italian Unit)
Identification, validation and commercial development of new diagnostic and prognostic biomarkers for complex trait diseases. (IVASCOMAR)	Italian Ministry of Research & EU Social Fund	2014-2017	Investigator
Biomarkers for Alzheimer's disease and Parkinson's disease (BIOMARKAPD)	EU Joint Programme – Neurodegenerative Disease Research (JPND Research)	2012-2015	Investigator
UNIMIB Competitive Funding	UNIMIB	2015-2018	Principal Investigator
CAA-ri Research	Prince Turki Al Saud Donation	2013-15	Principal Investigator
iCA β -ITALY	Italian Society for the study of Dementia (SINdem)	2014-2016	Coordinator
Biomarkers for modifiable risk factors and therapeutic intervention in AD and MS	Merck Serono	2011-2014	Co-PI
Network Enabled Drug Design (NED)	Regione Lombardia	2010-2013	Investigator
Nanoparticles for therapy and Diagnosis of Alzheimer's disease (NAD)	FP7-NMP-2007-LARGE-1 EU Social Funds	2008-2013	Investigator
Production of naturally secreted forms of low-n-oligomers of Abeta for the study of BACE1 metabolism	Fond. Banca del Monte di Lombardia, Progetto Professionalita' Ivano Becchi	2009-2010	Principal Investigator
Markers of Vascular Damage in AD	Reg. Lombardia, EU Social Fund -Applied Research in Neuroscience	2007-2008	Principal Investigator
Abeta production and clearance in patients with AD and MCI, in vitro studies and ex vivo markers	Italian Ministry of University and Research	2006-2009	Investigator

- Si autorizza il trattamento dei propri dati personali ai sensi del D. Lgs. n. 196 del 30/06/2003.
- Il presente CV ha funzione di autocertificazione ai sensi del D.P.R. n. 445 del 28/12/2000.

Monza, li __14/12/2017__

Firma